|Venture Round, 9/2010 ||$500k|
|Venture Round, 11/2010 ||$250k|
|Venture Round, 1/2011 ||$640k|
|Venture Round, 6/2013 ||$1.35M|
|Debt, 8/2011 ||$5M|
Genesis Biopharma, Inc. Merge with Lion Biotechnologies, Inc.
Genesis Biopharma, Inc. (OTCBB: GNBP) is developing autologous cell therapies for the treatment of cancer.
Our lead product candidate, Cōntego™, is an autologous cell therapy using tumor infiltrating lymphocytes (TILs) indicated for the treatment of metastatic melanoma. Cōntego™ is being developed as a ready-to-infuse autologous cell therapy product. Following resection of the patient’s tumor, TILs are isolated from the resected tumor, and expanded in vitro to several billion cells. The expanded TILs are then infused into the patient where they attack the melanoma tumors regardless of their location in the body.
Cōntego™ is based on the adoptive cell therapy regimen using tumor infiltrating lymphocytes invented by Dr. Steven A. Rosenberg, Chief, Surgery Branch, Center for Cancer Research, National Cancer Institute for the treatment of metastatic melanoma. Dr. Rosenberg’s adoptive cell therapy is presently available as a physician-sponsored investigational therapy for the treatment of Stage IV metastatic melanoma at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.